About Avalo Therapeutics, Inc.
https://www.avalotx.comAvalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases.
CEO
Garry A. Neil
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-12-29 | Reverse | 1:240 |
| 2022-07-08 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 3 of 16
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BVF INC/IL
Shares:1.36M
Value:$21.94M
ORBIMED ADVISORS LLC
Shares:1.35M
Value:$21.85M
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:1.24M
Value:$19.99M
Summary
Showing Top 3 of 72
About Avalo Therapeutics, Inc.
https://www.avalotx.comAvalo Therapeutics, Inc., a clinical-stage precision medicine company, discovers, develops, and commercializes targeted therapeutics for patients with unmet clinical need in immunology, immuno-oncology, and rare genetic diseases.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $19.2M ▼ | $-30.63M ▼ | 0% | $-2.19 ▼ | $-30.55M ▼ |
| Q2-2025 | $0 | $19.32M ▲ | $-20.77M ▼ | 0% | $-1.92 ▼ | $-19.18M ▼ |
| Q1-2025 | $0 ▼ | $14.67M ▲ | $-13.15M ▲ | 0% ▲ | $-1.25 ▼ | $-14.53M ▼ |
| Q4-2024 | $192K ▼ | $13.42M ▼ | $-35.34M ▼ | -18.41K% ▼ | $13.89 ▲ | $-13.24M ▼ |
| Q3-2024 | $249K | $13.82M | $23.04M | 9.25K% | $2.83 | $-12.83M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $111.62M ▼ | $125.1M ▼ | $33.55M ▲ | $91.55M ▼ |
| Q2-2025 | $113.26M ▼ | $126.58M ▼ | $22.01M ▲ | $104.57M ▼ |
| Q1-2025 | $125.05M ▼ | $138.52M ▼ | $15.91M ▼ | $122.61M ▼ |
| Q4-2024 | $134.55M ▲ | $150.73M ▲ | $17.7M ▼ | $133.03M ▲ |
| Q3-2024 | $81.86M | $98.45M | $77.38M | $21.08M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-30.63M ▼ | $-16.36M ▼ | $-13.26M ▲ | $14.37M ▲ | $-15.26M ▲ | $-16.36M ▼ |
| Q2-2025 | $-20.77M ▼ | $-11.39M ▼ | $-70.86M ▼ | $-469K ▼ | $-82.8M ▼ | $-11.39M ▼ |
| Q1-2025 | $-13.15M ▲ | $-9.46M ▲ | $0 | $0 ▼ | $-9.46M ▼ | $-9.46M ▲ |
| Q4-2024 | $-35.34M ▼ | $-15.04M ▼ | $0 | $67.71M ▲ | $52.67M ▲ | $-15.04M ▼ |
| Q3-2024 | $23.04M | $-11.53M | $0 | $0 | $-11.53M | $-11.53M |
Revenue by Products
| Product | Q4-2023 | Q3-2023 | Q3-2024 | Q4-2024 |
|---|---|---|---|---|
 Product | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Garry A. Neil
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2023-12-29 | Reverse | 1:240 |
| 2022-07-08 | Reverse | 1:12 |
ETFs Holding This Stock
Summary
Showing Top 3 of 16
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 2 of 2
Price Target
Institutional Ownership
BVF INC/IL
Shares:1.36M
Value:$21.94M
ORBIMED ADVISORS LLC
Shares:1.35M
Value:$21.85M
NANTAHALA CAPITAL MANAGEMENT, LLC
Shares:1.24M
Value:$19.99M
Summary
Showing Top 3 of 72